Many IBD 50 Stocks Struggle To Climb After Breakouts
at Investor's Business Daily - Fri Jun 27, 6:08PM CDT
A number of IBD 50 stocks have cleared buy points recently, but many of them have made little progress. Noneof the stocks is flashing a sell signal, but many of the bases are riskier late-stage patterns. As a result, investors should remain vigilant,...
Auxilium and QLT to Merge on Tax Saving Attractions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 11:10AM CDT
Auxilium (AUXL) and QLT (QLTI) will combine by year end.
Novo, Other Medicals Display Healthy Action
at Investor's Business Daily - Thu Jun 26, 5:41PM CDT
Leaders in buy range could get tougher to find as the market uptrend continues and stocks break out to new highs. But a raft of medical plays in today's Your Weekly Review are showing fairly healthy action as they work on bases or move near buy...
Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva
PR Newswire - Thu Jun 26, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.
World Market for Pain Management Drugs and Devices to 2017
M2 - Thu Jun 26, 2:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xbzv4k/the_world_market) has announced the addition of the "The World Market for Pain Management Drugs and Devices" report to their offering. The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the biochemical and neurophysiological factors that influence pain. The future of pain management will likely involve multidisciplinary departments dedicated to finding treatments that manage pain. The need is great worldwide for management of pain and there are still many facets of pain management that need to be explored. Faced with intensifying competition and increasingly price sensitive markets, manufacturers in the area of pain management therapeutics are trying to differentiate their products to avoid price competition and to increase profits. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer's ability to successfully operate in the market. A keen awareness of all facets of the industry including barriers will enable manufacturers to effectively challenge these issues and formulate plans to reduce or eliminate barriers in the treatment of pain. The driving forces for this market include growth and aging of the global population, new products and technology, and increasing interest in multidisciplinary approaches to pain management. The World Market for Pain Management Drugs and Devices, provides market estimates and forecasts for the following therapeutic categories: - Burn Pain - Cancer Pain - Dental/Facial Pain - Migraine Headache Pain - Musculoskeletal Pain - Neuropathic Pain - Obstetrical Pain - Pediatric Pain - Surgical and Trauma Pain This report details the various categories of top prescription pain management drugs, describes U.S., European, Japanese and other markets in each of the specific pain areas. The report also covers drug delivery methods, pain management devices, and alternate treatment modalities that are influencing the market. It further identifies major market factors, which are discussed, and a total market summary is presented. As part of the study the following competitors are profiled: - Abbott Laboratories - Actavis, Inc (formerly Watson Pharmaceuticals, Inc.) - AstraZeneca plc. - Baxter International, Inc. - BioDelivery Sciences International (BDSI) - Boehringer Ingelheim - Boston Scientific - Bristol-Myers Squibb Company - DepoMed - DURECT Corporation - Eli Lilly & Co. - Endo Health Solutions Inc - GlaxoSmithKline plc - Grunenthal Group - Medtronic, Inc. - Merck & Co. - Novartis - Pain Therapeutics, Inc - Pfizer, Inc - Purdue Pharma - QRx Pharma - Sanofi - St. Jude Medical, Inc - TEVA Pharmaceuticals Industries, Ltd - The Medicines Company - Valeant Pharmaceuticals International, Inc. - Zogenix, Inc. For more information visit http://www.researchandmarkets.com/research/xb...rld_market
Endo International to Expand Generics Business with DAVA Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 2:20PM CDT
Endo (ENDP) has inked a deal to buy DAVA Pharmaceuticals for a cash consideration of approximately $575 million.
Love the Stocks Everyone Hates: 5 Short-Squeeze Stocks Ready to Pop
at The Street - Wed Jun 25, 9:34AM CDT
These heavily shorted stocks could get squeezed on any positive catalyst.
Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.
Are Investors Wrong About VIVUS?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 24, 4:30PM CDT
Whenever short-sellers start jumping into a stock with both feet, it's generally a good idea to understand why. VIVUS has seen its short interest skyrocket this year to over 35% of the float, while the company's share price has subsequently...
Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
Business Wire - Tue Jun 24, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis' planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the "Election Deadline"
Major Indexes Narrowly Lower As Actavis Rallies
at Investor's Business Daily - Mon Jun 23, 12:29PM CDT
Despite better-than-expected economic data, the major averages were still trading flat to slightly lower in early-afternoon trading. The Nasdaq was flat, while the S&P 500 edged down 0.1% and the Dow industrials eased 0.2%. Volume was tracking well...
3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Unusual Social Activity Today Around Actavis (ACT)
at The Street - Mon Jun 23, 10:41AM CDT
Trade-Ideas LLC identified Actavis (ACT) as an unusual social activity candidate
Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
Business Wire - Mon Jun 23, 7:30AM CDT
--- Proven Development Track Record in Key Therapeutic Categories including Women's Health, Psychiatric and Cardiovascular -
Settlements, Statements, FDA Submissions and Approvals - Analyst Notes on Valeant, Pfizer, Actavis, Allergan and Teva
PR Newswire - Fri Jun 20, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Allergan, Inc. (NYSE: AGN) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3940-100free.
Teva's Nuvigil Patent Infringement Lawsuits Resolved - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 3:45PM CDT
Teva (TEVA) settled its patent infringement lawsuits for Nuvigil with Sandoz, Actavis (ACT), Lupin and Apotex.
Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.